Overview
Comprehensive Female I analyses a range of hormones and biochemical markers through saliva and bloodspot samples to offer a broad perspective on hormonal balance. Saliva samples are used to assess steroid hormones such as oestradiol, progesterone, testosterone, DHEA-S and cortisol, which represent the bioavailable portions active in the body. Meanwhile, bloodspot samples provide measures of thyroid-related markers including TSH, free T3, free T4 and thyroid peroxidase antibodies. This combination supports understanding of multiple endocrine systems within one testing profile.
This panel can support exploration of complex hormonal interactions by integrating adrenal, thyroid and sex hormone data together, which may aid in generating insights into factors influencing energy, mood, metabolic function and overall wellbeing. Considering multiple hormone systems simultaneously helps to identify patterns and relationships that might be missed when examining individual markers alone. Results are best viewed alongside lifestyle factors, daily patterns, and any current personal health approaches for a comprehensive overview.
By evaluating these interconnected hormone markers, Comprehensive Female I offers a multifaceted look at hormonal activity that can be informative for personal wellness and research interests. The data may contribute to a deeper understanding of hormone-related influences on everyday comfort, stress responses and physiological rhythms. This profile utilises established sampling techniques to present an integrated hormonal snapshot that can support curiosity and optimisation in a non-clinical context.
Comprehensive Female I is intended for informational, educational, wellness and/or research purposes only. It is not intended for use in medical diagnosis, disease screening or clinical decision-making. Comprehensive Female I is not a replacement for clinical laboratory testing and does not provide medical diagnoses. This content is intended for general information within the EU market and should not be interpreted as a regulated in-vitro diagnostic claim.
Practical
Downloads
23-Apr-2024
23-Apr-2024